DE69007319D1 - Zusammensetzungen zur Behandlung von Neoplasia mit Gehalt an neoplasmushemmendem Mittel und Nebenwirkungen reduzierendem Schutzmittel. - Google Patents

Zusammensetzungen zur Behandlung von Neoplasia mit Gehalt an neoplasmushemmendem Mittel und Nebenwirkungen reduzierendem Schutzmittel.

Info

Publication number
DE69007319D1
DE69007319D1 DE90107246T DE69007319T DE69007319D1 DE 69007319 D1 DE69007319 D1 DE 69007319D1 DE 90107246 T DE90107246 T DE 90107246T DE 69007319 T DE69007319 T DE 69007319T DE 69007319 D1 DE69007319 D1 DE 69007319D1
Authority
DE
Germany
Prior art keywords
side effects
treatment
neoplasmic
inhibitor
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE90107246T
Other languages
English (en)
Other versions
DE69007319T2 (de
Inventor
Ardalan Bach
William R Shanahan Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of DE69007319D1 publication Critical patent/DE69007319D1/de
Publication of DE69007319T2 publication Critical patent/DE69007319T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE69007319T 1989-04-17 1990-04-17 Zusammensetzungen zur Behandlung von Neoplasia mit Gehalt an neoplasmushemmendem Mittel und Nebenwirkungen reduzierendem Schutzmittel. Expired - Fee Related DE69007319T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33950389A 1989-04-17 1989-04-17

Publications (2)

Publication Number Publication Date
DE69007319D1 true DE69007319D1 (de) 1994-04-21
DE69007319T2 DE69007319T2 (de) 1994-08-04

Family

ID=23329296

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69007319T Expired - Fee Related DE69007319T2 (de) 1989-04-17 1990-04-17 Zusammensetzungen zur Behandlung von Neoplasia mit Gehalt an neoplasmushemmendem Mittel und Nebenwirkungen reduzierendem Schutzmittel.

Country Status (8)

Country Link
EP (1) EP0393575B1 (de)
JP (1) JPH02292227A (de)
AT (1) ATE102838T1 (de)
CA (1) CA2014732A1 (de)
DE (1) DE69007319T2 (de)
DK (1) DK0393575T3 (de)
ES (1) ES2062155T3 (de)
PT (1) PT93772A (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5493017A (en) * 1992-08-14 1996-02-20 The Trustees Of The University Of Pennsylvania Ring-metalated porphyrins
US5599924A (en) * 1992-08-14 1997-02-04 Trustees Of The University Of Pennsylvania Electron-deficient porphyrins and processes and intermediates for preparing same
US5371199B1 (en) * 1992-08-14 1995-12-26 Univ Pennsylvania Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor
US5817830A (en) * 1992-08-14 1998-10-06 Trustees Of The University Of Pennsylvania Pyrrolic compounds
US5378456A (en) * 1993-03-25 1995-01-03 American Cyanamid Company Antitumor mitoxantrone polymeric compositions
US5569667A (en) * 1995-01-19 1996-10-29 Warner-Lambert Company Treatment of prostate cancer
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
PT874630E (pt) * 1996-01-11 2004-01-30 Topotarget Aps Terapia combinada de um inibidor da topoisomerase ii e um derivado da bis-dioxipiperazina
US6265385B1 (en) 1996-01-11 2001-07-24 Topo Target Aps Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy
DE69734713T2 (de) * 1996-05-14 2006-07-06 Burzynski, Stanislaw R., Houston Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
US5783689A (en) * 1996-11-12 1998-07-21 University Of Notre Dame Antibacterial and antifungal nucleosides
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
EP1223923B1 (de) * 1999-10-12 2010-03-31 Temple University of the Commonwealth System of Higher Education Ungesättigte arylsulfone zum schutz von normalen zellen gegen die zytotoxische wirkung von chemotherapeutika
US6767926B1 (en) 1999-10-12 2004-07-27 Temple University - Of The Commonwealth System Of Higher Education Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
AT408719B (de) * 2000-03-22 2002-02-25 Nowicky Wassili Mittel zur behandlung von hepatitis c
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
US20020128258A1 (en) * 2001-03-09 2002-09-12 Jean-Pierre Robin Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
ES2341922T3 (es) 2001-11-01 2010-06-29 Spectrum Pharmaceuticals, Inc. Composiciones medicas para el tratamiento intravesical de cancer de vejiga.
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
WO2003053407A1 (en) * 2001-12-19 2003-07-03 Research Development Foundation Liposomal delivery of vitamin e based compounds
AU2003214462A1 (en) 2002-04-03 2003-10-13 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
FR2863892B1 (fr) * 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
WO2005111055A1 (ja) * 2004-04-28 2005-11-24 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai 新規抗生物質キガマイシン類とその用途
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP2750768B1 (de) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabin-derivat zubereitungen
WO2014179528A2 (en) * 2013-05-01 2014-11-06 Brown Dennis M Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
JP6768722B2 (ja) 2015-07-02 2020-10-14 大塚製薬株式会社 凍結乾燥医薬組成物
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
CN116019798B (zh) * 2022-07-20 2024-03-12 中南大学湘雅二医院 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255537A (en) * 1979-01-22 1981-03-10 Monsanto Company Polymeric immunoregulatory agents containing half-amide/half carboxy/imide groups

Also Published As

Publication number Publication date
JPH02292227A (ja) 1990-12-03
CA2014732A1 (en) 1990-10-17
PT93772A (pt) 1991-01-08
DE69007319T2 (de) 1994-08-04
ATE102838T1 (de) 1994-04-15
EP0393575B1 (de) 1994-03-16
DK0393575T3 (da) 1994-04-05
ES2062155T3 (es) 1994-12-16
EP0393575A1 (de) 1990-10-24

Similar Documents

Publication Publication Date Title
DE69007319D1 (de) Zusammensetzungen zur Behandlung von Neoplasia mit Gehalt an neoplasmushemmendem Mittel und Nebenwirkungen reduzierendem Schutzmittel.
EP2295063A3 (de) Zusammensetzungen und deren Verwendung zur Behandlung von Erkrankungen der Mitochondrien
SE9301951D0 (sv) Methods for administration of taxol
LV10924A (lv) Sintetiskie katalitiskie brivo radikalu akceptori kurus izmanto ka antioksidantus slimibu profilaksei un arstesanai
TW250435B (de)
TW362971B (en) Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti
TR200102005T2 (tr) Poli(adp-ribaz) polimerazların trisiklik inhibitörleri.
DK0612248T3 (da) Præparat, der indeholder cisplatin og topotecan som antitumormiddel
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
FI895141A0 (fi) Kelatmedel med orto-ligerande funktionalitet och deras komplexer.
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
IL118218A (en) Pharmaceutical compositions containing sarcodictyins
CA2078544A1 (en) Method and compositions for treating injury
ES2012547A6 (es) Procedimiento para preparar una composicion farmaceutica que contiene metaloporfirinas.
EP1374873B8 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie
DE69330809T2 (de) Therapeutisches Agens für Neutropenie
GR3029898T3 (en) Use of Etofibrate and pharmaceutical compositions containing etofibrate in the treatment of diabetic angio- and retinopathy.
JO1708B1 (en) The use of trinitrobenzene or cochineal acid in the treatment of cancer or genital diseases
IT1236834B (it) Complessi del 4-idrossi-2-metil-n--2-piridinil-2-h,2-benzotiazina-3- carbossiammide-1,1-diossido con cilodestrine, aventi azione anti- infiammatoria, procedimento per la loro preparazione e relative composizioni farmaceutiche.
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica
ATE227573T1 (de) Orale oder intramuskuläre behandlung von pankreaskrebs durch wasserunlösliches s- camptothecin mit geschlossenem lactonring

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee